Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.

Literature DB >> 18508133

CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.

Che Liu¹, Defang Luo, Wolfgang J Streit, Jeffrey K Harrison.

Abstract

Human glioblastoma multiforme (GBM) is the most malignant form of human brain tumors. A characteristic of GBM is the marked presence of tumor infiltrated microglia/macrophages and lymphocytes. The goal of this study was directed toward understanding the role of the chemokine system CX3CL1 and its receptor CX3CR1 in the GL261 murine model of malignant glioma. In situ hybridization analysis identified CX3CL1 and CX3CR1 expression in GL261 tumors. The impact of CX3CR1 deletion on the growth of intracranial GL261 gliomas and associated immune cell infiltration was evaluated in CX3CR1 gene-disrupted C57BL/6 mice. A slight increase in the tumor growth rate in CX3CR1-/- mice was evident with similar numbers of microglia and CD4+, CD8+, FoxP3+, or Ly49G2+ lymphocytes within tumors established in CX3CR1 +/- and -/- mice. These data indicate that CX3CR1 has little or no effects on either gliomagenesis or the migration of microglia and lymphocytes into GL261 tumors.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18508133 PMCID： PMC2561213 DOI： 10.1016/j.jneuroim.2008.04.016

Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478

39 in total

1. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation.

Authors: V Zujovic; J Benavides; X Vigé; C Carter; V Taupin
Journal: Glia Date: 2000-02-15 Impact factor: 7.452

2. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

Authors: Eileen J McMahon; Samantha L Bailey; Carol Vanderlugt Castenada; Hanspeter Waldner; Stephen D Miller
Journal: Nat Med Date: 2005-02-27 Impact factor: 53.440

3. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors: Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal: J Clin Invest Date: 2007-01 Impact factor: 14.808

4. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.

Authors: S Jung; J Aliberti; P Graemmel; M J Sunshine; G W Kreutzberg; A Sher; D R Littman
Journal: Mol Cell Biol Date: 2000-06 Impact factor: 4.272

5. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Authors: L Gorelik; R A Flavell
Journal: Nat Med Date: 2001-10 Impact factor: 53.440

Review 6. Dendritic cell based personalized immunotherapy based on cancer antigen research.

Authors: Yutaka Kawakami; Tomonobu Fujita; Chie Kudo; Toshiharu Sakurai; Masaru Udagawa; Tomonori Yaguchi; Go Hasegawa; Emiko Hayashi; Yoko Ueda; Tomoko Iwata; Qinfu Wang; Starlyn Okada; Nobuo Tsukamoto; Yuriko Matsuzaki; Hidetoshi Sumimoto
Journal: Front Biosci Date: 2008-01-01

7. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors: Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal: Proc Natl Acad Sci U S A Date: 2007-09-26 Impact factor: 11.205

8. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth.

Authors: Linda W Horton; Yingchun Yu; Snjezana Zaja-Milatovic; Robert M Strieter; Ann Richmond
Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701

9. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration.

Authors: Jingsheng Tuo; Christine M Bojanowski; Min Zhou; Defen Shen; Robert J Ross; Kevin I Rosenberg; D Joshua Cameron; Chunyue Yin; Jeffrey A Kowalak; Zhengping Zhuang; Kang Zhang; Chi-Chao Chan
Journal: Invest Ophthalmol Vis Sci Date: 2007-08 Impact factor: 4.799

10. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration.

Authors: Christophe Combadière; Charles Feumi; William Raoul; Nicole Keller; Mathieu Rodéro; Adeline Pézard; Sophie Lavalette; Marianne Houssier; Laurent Jonet; Emilie Picard; Patrice Debré; Mirna Sirinyan; Philippe Deterre; Tania Ferroukhi; Salomon-Yves Cohen; Dominique Chauvaud; Jean-Claude Jeanny; Sylvain Chemtob; Francine Behar-Cohen; Florian Sennlaub
Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808

26 in total

1. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors: Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal: Proc Natl Acad Sci U S A Date: 2019-12-26 Impact factor: 11.205

2. CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.

Authors: Kien Pham; Defang Luo; Che Liu; Jeffrey K Harrison
Journal: J Neuroimmunol Date: 2012-03-16 Impact factor: 3.478

CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.

1. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation.

2. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

3. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

4. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.

5. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Review 6. Dendritic cell based personalized immunotherapy based on cancer antigen research.

7. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

8. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth.

9. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration.

10. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration.

1. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

2. CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.

3. Chemokine receptor CXCR3 promotes growth of glioma.

Review 4. The role of microglia and macrophages in glioma maintenance and progression.

5. Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

6. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1.

7. Hematopoietic- and neurologic-expressed sequence 1 expression in the murine GL261 and high-grade human gliomas.

8. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

9. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Review 10. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications.